Illumina (ILMN)
(Delayed Data from NSDQ)
$117.61 USD
+3.12 (2.73%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $117.69 +0.08 (0.07%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth D Momentum C VGM
Illumina (ILMN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$145.43 | $242.00 | $100.00 | 27.02% |
Price Target
Based on short-term price targets offered by 21 analysts, the average price target for Illumina comes to $145.43. The forecasts range from a low of $100.00 to a high of $242.00. The average price target represents an increase of 27.02% from the last closing price of $114.49.
Analyst Price Targets (21)
Broker Rating
Illumina currently has an average brokerage recommendation (ABR) of 2.20 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 20 brokerage firms. The current ABR compares to an ABR of 2.30 a month ago based on 20 recommendations.
Of the 20 recommendations deriving the current ABR, nine are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 45% and 5% of all recommendations. A month ago, Strong Buy made up 40%, while Buy represented 5%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ILMN.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 8 | 8 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 8 | 8 | 9 | 8 | 8 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.20 | 2.20 | 2.30 | 2.26 | 2.26 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/10/2024 | Not Identified | Not Identified | Hold | Strong Buy |
7/10/2024 | Stephens | Mason Carrico | Strong Buy | Strong Buy |
6/20/2024 | Guggenheim Securities | Subbu Nambi | Strong Buy | Strong Buy |
6/11/2024 | Evercore Partners | Vijay Kumar | Strong Buy | Strong Buy |
6/6/2024 | SVB Securities | Puneet Souda | Strong Buy | Strong Buy |
6/3/2024 | Not Identified | Not Identified | Not Available | Hold |
5/6/2024 | Scotiabank | Sung-Ji Nam | Strong Buy | Strong Buy |
5/3/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/10/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
4/9/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
4/1/2024 | Cowen & Co. | Daniel Brennan | Hold | Hold |
3/1/2024 | Piper Sandler | David M Westenberg | Strong Buy | Strong Buy |
2/8/2024 | Robert W. Baird & Co. | Catherine W Schulte | Hold | Hold |
1/16/2024 | Not Identified | Not Identified | Strong Buy | Hold |
12/15/2023 | Not Identified | Not Identified | Strong Sell | Hold |
12/13/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
11/10/2023 | Canaccord Genuity | Kyle Mikson | Strong Buy | Hold |
11/10/2023 | UBS | John N Sourbeer | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.20 |
ABR (Last week) | 2.20 |
# of Recs in ABR | 20 |
Average Target Price | $145.43 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | 0.23 |